Genetics of Alzheimer’s disease and frontotemporal dementia

Current Molecular Medicine

Volumn 14, Issue 8, 2014, Pages 993-1000

  Nacmias, B ^a   Piaceri, I ^a   Bagnoli, S ^a   Tedde, A ^a   Piacentini, S ^a   Sorbi, S ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Alzheimer s disease; Dementia; Frontotemporal dementia; Genetics; GWAS; Mutation

Indexed keywords

CD2 ASSOCIATED PROTEIN; COMPLEMENT COMPONENT C3 RECEPTOR; FLUORODEOXYGLUCOSE F 18; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR GENETICS; CLINICAL FEATURE; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC ASSOCIATION; GLUCOSE METABOLISM; HUMAN; POSITRON EMISSION TOMOGRAPHY;

EID: 84911480966     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524014666141010152143     Document Type: Article

References (75)

1. Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer's disease. Lancet Neurol 2013; 12(1): 92-104.
2. Honig LS. Translational research in neurology: dementia. Arch Neurol 2012; 69(8): 969-977.
3. th, 2013].
4. Sjogren T, Sjogren H, Lindgren AG. Morbus Alzheimer and morbus Pick; a genetic, clinical and patho-anatomical study. Acta Psychiatr Neurol Scand Suppl 1952; 82: 1-152.
5. Lambert JC, Grenier-Boley B, Harold D, et al. Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. Mol Psychiatry 2013; 18(4): 461-470.
6. Goldman JS. New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration. Curr Neurol Neurosci Rep 2012; 12(5): 502-510.
7. Kwon JM, Steiner RD. "I'm fine; I'm just waiting for my disease": the new and growing class of presymptomatic patients. Neurology 2011; 77(6): 522-523.
8. Karlawish J. Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology 2011; 77(15): 1487-1493.
9. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012; 69(2): 198-207.
10. Miller G. Alzheimer's research. Stopping Alzheimer's before it starts. Science 2012; 337(6096): 790-792.
11. Piaceri I, Nacmias B, Sorbi S. Genetics of familial and sporadic Alzheimer's disease. Front Biosci (Elite Ed) 2013; 5: 167-177.
12. th, 2013].
13. Goate A, Chartier-Harlin MC, Mullan M, et al. Crawford Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-706.
14. Goate A, Hardy J. Twenty years of Alzheimer's disease-causing mutations. J Neurochem 2012; 120 Suppl 1: 3-8.
15. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the role of Alzheimer's disease in late onset families. Science 1993; 26: 921-923.
16. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92(11): 4725-4727.
17. Genin E, Hannequin D, Wallon D, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011; 16(9): 903-907.
18. St. George-Hyslop P, Tanzi RE, Polinsky R, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987; 235: 885-890.
19. Sorbi S, Nacmias B, Forleo P, et al. APP717 and Alzheimer's disease in Italy. Nat Genet 1993; 4: 10.
20. Mosconi L, Sorbi S, Nacmias B, et al. A. Brain metabolic differences between sporadic and familial Alzheimer's disease. Neurology 2003; 61(8): 1138-1140.
21. Mosconi, L, Perani, D, Sorbi, S, et al. MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET. Neurology 2004; 63: 2332-2340.
22. Mosconi L, Brys M, Glodzik-Sobanska L, et al. Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol 2007; 42: 129-138.
23. Mosconi L, Sorbi S, de Leon MJ, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 2006; 47(11): 1778-1786.
24. Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a crosssectional study. Lancet Neurol 2012; 11(12): 1057-1065.
25. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012; 11(12): 1048-1056.
26. Bateman RJ, Xiong C, Benzinger TL, et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367(9): 795-804.
27. Moraes CF, Lins TC, Carmargos EF, Naves JO, Pereira RW, Nóbrega OT. Lessons from genome-wide association studies findings in Alzheimer's disease. Psychogeriatrics 2012; 12(1): 62-73.
28. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41(10): 1094-1099.
29. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088-1093.
30. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43: 436-441.
31. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43: 429-435.
32. Holton P, Ryten M, Nalls M, et al. Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann Hum Genet 2013; 77(2): 85-105.
33. Pawitan Y, Seng KC, Magnusson PK. How many genetic variants remain to be discovered? PLoS One 2009; 4(12): e7969.
34. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368(2): 117-127.
35. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368(2): 107-116.
36. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012; 488(7409): 96-99.
37. Kero M, Paetau A, Polvikoski T, et al. Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population. Neurobiol Aging 2013; 34(5): 1518. e1-3.
38. Jahanshad N, Rajagopalan P, Hua X, et al. Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proc Natl Acad Sci U S A 2013; 110(12): 4768-4773.
39. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010; 9(10): 995-1007.
40. Galimberti D, Scarpini E. Clinical phenotypes and genetic biomarkers of FTLD. J Neural Transm 2012; 119(7): 851-860.
41. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134(Pt 9): 2456-2477.
42. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76(11): 1006-1014.
43. Lynch T, Sano M, Marder KS, et al. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 1994; 44(10): 1878-1884.
44. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72(2): 245-256.
45. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72(2): 257-268.
46. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia fTdP-17. Nature 1998; 393: 702-705.
47. Poorkaj P, Bird TD, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998; 43: 815-825.
48. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 1998; 95: 7737-7741.
49. Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 2012; 8(8): 423-434.
50. Mori K, Weng SM, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013; 339(6125): 1335-1338.
51. Borroni B, Padovani A. Dementia: A new algorithm for molecular diagnostics in FTLD. Nat Rev Neurol 2013; 9(5): 241-242.
52. Van Langenhove T, van der Zee J, Gijselinck I, et al. Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and non mutation carriers in a Flanders-Belgian FTLD cohort. JAMA Neurol 2013; 70(3): 365-373.
53. Guerreiro RJ, Lohmann E, Brás JM, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol 2013; 70(1): 78-84.
54. Van Deerlin VM, Sleiman PM, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010; 42(3): 234-239.
55. Nicholson AM, Finch NA, Wojtas A, et al. TMEM106B p. T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J Neurochem 2013; 126(6): 781-791.
56. Sieben A, Van Langenhove T, Engelborghs S, et al. The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol 2012; 124(3): 353-372.
57. Pan XD, Chen XC. Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review. Transl Neurodegener 2013; 2(1): 8.
58. Pastor P, Pastor E, Carnero C, et al. Familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene. Ann Neurol 2001; 49: 263-267.
59. Nicholl DJ, Greenstone MA, Clarke CE, et al. An English kindred with a novel recessive tauopathy and respiratory failure. Ann Neurol 2003; 54: 682-686.
60. Bessi V, Bagnoli S, Nacmias B, Tedde A, Sorbi S, Bracco L. Semantic dementia associated with mutation V363I in the tau gene. J Neurol Sci 2010; 296(1-2): 112-114.
61. Munoz DG, Ros R, Fatas M, Bermejo F, de Yebenes JG. Progressive nonfluent aphasia associated with a new mutation V363I in tau gene. Am J Alzheimers Dis Other Demen 2007; 22(4): 294-299.
62. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442(7105): 916-919.
63. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006; 442(7105): 920-924.
64. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin l evels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 2008; 71(16): 1235-1239.
65. Cruts M, Van Broeckhoven C. Loss of progranulin function in frontotemporal lobar degeneration. Trends Genet 2008; 24(4): 186-194.
66. Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 2012; 33(9): 1340-1344.
67. Le Ber I, van der Zee J, Hannequin D, et al. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat 2007; 28(9): 846-855.
68. Bagnoli S, Piaceri I, Tedde A, et al. Progranulin genetic screening in frontotemporal lobar degeneration patients from central Italy. Cell Mol Neurobiol 2012; 32(1): 13-16.
69. van der Zee J, Gijselinck I, Dillen L, et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat 2013; 34(2): 363-373.
70. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11(4): 323-330.
71. Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 2012; 135(Pt 3): 693-708.
72. Dobson-Stone C, Hallupp M, Bartley L, et al. C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology 2012; 79(10): 995-1001.
73. Galimberti D, Fenoglio C, Serpente M, et al. Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. Biol Psychiatry 2013; 74(5): 384-391.
74. Riedijk SR, Niermeijer MFN, Dooijes D, Tibben A. A decade of genetic counseling in frontotemporal dementia affected families: Few counseling requests and much familial opposition to testing. J Genet Couns 2009; 18: 350-356.
75. Cohn-Hokke PE, Elting MW, Pijnenburg YA, van Swieten JC. Genetics of dementia: update and guidelines for the clinician. Am J Med Genet B Neuropsychiatr Genet 2012; 159B(6): 628-643.